Drug intelligence / Profile preview

ACT201

Development stage: Phase 1
Lead developer: Xiamen Tebao Biological Engineering
Modality: Small Molecules

Overview

ACT201 is an investigational small molecule immunomodulator currently in preclinical development by Xiamen Amoytop Biotech for the treatment of chronic hepatitis B (CHB). It is part of a pipeline of innovative drug candidates, which includes ACT400 and ACT560, aimed at achieving a functional cure for hepatitis B virus (HBV) infection. While the specific molecular target of ACT201 has not been publicly disclosed, it is categorized within Xiamen Amoytop's immunology portfolio and is designed to modulate the host immune system to facilitate the clearance of HBV.

Targets

HBV X RNA (Hepatitis B virus X region RNA transcript)TLR8 (Toll-like receptor 8)HBV (Hepatitis B virus)

Beyond the preview

Go deeper on ACT201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACT201.